SCHEMBL30385702

SCHEMBL30385702

CCc1cc(Nc2nccn3c(-c4ccc(Cl)c(F)c4F)cnc23)ccc1C(=O)NCCCNC(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 1/20 0.40
▸ PTK6 Q13882 2/20 0.38
▸ ACVR1B P36896 1/20 0.37
▸ TGFBR1 P36897 1/20 0.37
▸ ACVRL1 P37023 1/20 0.37
▸ TTK P33981 4/20 0.37
▸ STK17B O94768 1/20 0.36
▸ STK17A Q9UEE5 1/20 0.36
▸ JAK2 O60674 1/20 0.35
▸ NTRK1 P04629 1/20 0.35
▸ EGFR P00533 2/20 0.34
▸ ITK Q08881 2/20 0.34
▸ AURKB Q96GD4 2/20 0.34
▸ CSNK2A2 P19784 1/20 0.34
▸ CSNK2A1 P68400 1/20 0.34
▸ BRAF P15056 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ ABL1 P00519 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30386008 0.92 BRD4 (0.40) BRD4PTK6ACVR1BTGFBR1ACVRL1
SCHEMBL30384774 0.91 BRD4 (0.40) BRD4PTK6ACVR1BTGFBR1ACVRL1
SCHEMBL30349820 0.90 PTK6 (0.39) PTK6TTKNTRK1AURKBBRAF
SCHEMBL22125051 0.90 PTK6 (0.39) PTK6TTKNTRK1AURKBBRAF
SCHEMBL25173405 0.89 BRD4 (0.38) BRD4PTK6ACVR1BTGFBR1ACVRL1
SCHEMBL30385683 0.89 BRD4 (0.39) BRD4PTK6ACVR1BTGFBR1ACVRL1
SCHEMBL22123059 0.89 PTK6 (0.39) PTK6TTKAURKBCSNK2A2CSNK2A1
SCHEMBL24112523 0.89 PTK6 (0.41) PTK6TTKAURKBBRAFKDM4E
SCHEMBL30385204 0.88 BRD4 (0.38) BRD4PTK6ACVR1BTGFBR1ACVRL1
Hydrochloric Acid SCHEMBL25176396 0.88 PTK6 (0.39) PTK6TTKAURKBCSNK2A2CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4161931-B1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2026-02-18 — — EP disclosed
US-20230141600-A1 IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-05-11 — — US disclosed
EP-4161931-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2023-04-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230141600-A1 IMIDAZOPYRAZINE DERIVATIVES IKZF3, RRP15, IK BRD4 483/4885PTK6 925/4885ACVR1B 1338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback